Drug intelligence / Profile preview

BMS-986506

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986506 is an investigational oral small molecule developed by Bristol Myers Squibb for the treatment of advanced or metastatic clear cell renal cell carcinoma (ccRCC). It is currently being evaluated in a first-in-human Phase 1/1b clinical trial (NCT07195682 / NCT06263881) to assess its safety, tolerability, and pharmacokinetics in patients who have progressed on standard therapies, such as immune checkpoint inhibitors and VEGF-targeted therapies. The specific biological target and mechanism of action have not been publicly disclosed by the developer, but the agent is described as possessing a novel mechanism of action intended to target pathways distinct from those addressed by current standard-of-care treatments for kidney cancer.

Targets

CRBN (Cereblon)

Beyond the preview

Go deeper on BMS-986506.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986506.

Explore the full profile